复星医药(02196)：重酒石酸去甲肾上腺素注射液药品注册申请获批

Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical, has received approval from the National Medical Products Administration for the registration of a drug, which is indicated for the treatment of acute hypotensive states and as an auxiliary treatment for cardiac arrest [1] Group 1 - The approved drug is a formulation of dexmedetomidine hydrochloride injection, which is used to restore blood pressure in acute hypotensive states [1] - The drug can also assist in the treatment of cardiac arrest and maintain blood pressure after resuscitation [1] - It serves as an auxiliary treatment for shock caused by insufficient blood volume, temporarily maintaining cerebral and coronary perfusion until volume resuscitation takes effect [1]